Robert MacLaren
Corporate Officer/Principal bei University of Oxford
Profil
Robert MacLaren was the founder of NightstaRx Ltd.
(founded in 2014) and Nightstar Therapeutics Ltd.
(founded in 2014), where he held the title of Director and Independent Non-Executive Director, respectively.
Currently, he holds the position of Professor-Ophthalmology at the University of Oxford and Professor-Surgery at The Royal College of Surgeons of Edinburgh.
Dr. MacLaren obtained a doctorate degree from the University of Oxford and an undergraduate degree from The University of Edinburgh.
Aktive Positionen von Robert MacLaren
| Unternehmen | Position | Beginn |
|---|---|---|
| University of Oxford | Corporate Officer/Principal | - |
| The Royal College of Surgeons of Edinburgh | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Robert MacLaren
| Unternehmen | Position | Ende |
|---|---|---|
| NIGHTSTAR THERAPEUTICS PLC | Gründer | - |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Gründer | - |
Ausbildung von Robert MacLaren
| University of Oxford | Doctorate Degree |
| The University of Edinburgh | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
